Keith Stewart, MB, ChB from Mayo Clinic in Scottsdale, discusses the use of monoclonal antibodies for treatment in multiple myeloma.
Keith Stewart, MB, ChB from Mayo Clinic in Scottsdale, discusses the use of monoclonal antibodies for treatment in multiple myeloma.
The two monoclonal antibodies currently approved for treatment in patients with multiple myeloma are elotuzumab and daratumumab. While infusion reactions can occur with these treatments, there are pre-medications recommended. Additionally, most reactions are not usually experienced beyond the first infusion.
To learn more about these treatments, watch Safety of Monoclonal Antibodies in Myeloma.
Survival Benefit, Durable Responses Continue at 3 Years With Liso-cel in Second-line LBCL
July 15th 2024Three-year findings from the TRANSFORM trial provide further evidence that liso-cel should be considered as the new standard of care along with other CAR T-cell therapies for patients with primary refractory or relapsed LBCL, an expert said.